ATXS Astria Therapeutics Inc

Price (delayed)

$11.65

Market cap

$639.74M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.4

Enterprise value

$467.89M

Highlights
Astria Therapeutics's debt has shrunk by 79% YoY and by 49% QoQ
Astria Therapeutics's equity has surged by 74% YoY and by 51% QoQ
The net income has dropped by 71% year-on-year and by 12% since the previous quarter

Key stats

What are the main financial stats of ATXS
Market
Shares outstanding
54.91M
Market cap
$639.74M
Enterprise value
$467.89M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.74
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$81.63M
EBITDA
-$81.63M
Free cash flow
-$74.31M
Per share
EPS
-$2.4
Free cash flow per share
-$1.42
Book value per share
$6.7
Revenue per share
$0
TBVPS
$7.24
Balance sheet
Total assets
$378.81M
Total liabilities
$11.07M
Debt
$168,000
Equity
$367.74M
Working capital
$363.45M
Liquidity
Debt to equity
0
Current ratio
33.83
Quick ratio
33.41
Net debt/EBITDA
2.11
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-31.6%
Return on equity
-32.8%
Return on invested capital
-82.4%
Return on capital employed
-22.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATXS stock price

How has the Astria Therapeutics stock price performed over time
Intraday
-1.02%
1 week
-1.6%
1 month
23.54%
1 year
20.48%
YTD
51.69%
QTD
28.02%

Financial performance

How have Astria Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$93.69M
Net income
-$81.63M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 82% year-on-year and by 13% since the previous quarter
The net income has dropped by 71% year-on-year and by 12% since the previous quarter

Growth

What is Astria Therapeutics's growth rate over time

Valuation

What is Astria Therapeutics stock price valuation
P/E
N/A
P/B
1.74
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 13% YoY
Astria Therapeutics's equity has surged by 74% YoY and by 51% QoQ
The P/B is 35% higher than the 5-year quarterly average of 1.3 and 26% higher than the last 4 quarters average of 1.4

Efficiency

How efficient is Astria Therapeutics business performance
The ROIC has shrunk by 52% YoY but it has increased by 41% QoQ
ATXS's ROA is down by 12% YoY but it is up by 5% QoQ
Astria Therapeutics's return on equity has decreased by 11% YoY but it has increased by 5% QoQ

Dividends

What is ATXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATXS.

Financial health

How did Astria Therapeutics financials performed over time
ATXS's total assets has soared by 74% YoY and by 49% QoQ
ATXS's total liabilities has soared by 61% year-on-year but it is down by 4.1% since the previous quarter
Astria Therapeutics's debt is 100% lower than its equity
Astria Therapeutics's debt has shrunk by 79% YoY and by 49% QoQ
Astria Therapeutics's equity has surged by 74% YoY and by 51% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.